183735-18-4

Upstream product

• 823-78-9 meta-bromobenzyl bromide 
• 1074-82-4 potassium phtalimide 
• 136918-14-4 phthalimide 

Downstream Products

• 67907-53-3 benzylidene-(3-bromo-benzyl)-amine 
• 135996-84-8 (3-bromo-benzyl)-urea 
• 1616590-15-8 (4,4-dimethyl-3,4-dihydrocarbostyril)-6-carboxylic acid (E)-3-[2-(hydroxycarbamoyl)vinyl]benzylamide 
• 1616590-17-0 (4,4-dimethyl-3,4-dihydrocarbostyril)-7-carboxylic acid (E)-3-[2-(hydroxycarbamoyl)vinyl]benzylamide 
• 171663-13-1 t-butyl N-(3-bromobenzyl)carbamate 
• 1616590-39-6 C₂₄H₂₆N₂O₄ 
• 1616590-40-9 C₂₄H₂₆N₂O₄ 
• 214360-75-5 2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]isoindoline-1,3-dione 
• 10269-01-9 3-bromobenzylamine 

Relevant academic research and scientific papers

COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof.

Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors

Histone deacetylase (HDAC) inhibitions are known to elicit anticancer effects. We designed and synthesized several HDAC inhibitors. Among these compounds, compound 40 exhibited a more than 10-fold stronger inhibitory activity compared with that of suberoylanilide hydroxamic acid (SAHA) against each human HDAC isozyme in vitro (IC50 values of 40: HDAC1, 0.0038 μM; HDAC2, 0.0082 μM; HDAC3, 0.015 μM; HDAC8, 0.0060 μM; HDAC4, 0.058 μM; HDAC9, 0.0052 μM; HDAC6, 0.058 μM). The dose of the administered HDAC inhibitors that contain hydroxamic acid as the zinc-binding group may be reduced by 40. Because the carbostyril subunit is a time-tested structural component of drugs and biologically active compounds, 40 most likely exhibits good absorption, distribution, metabolism, excretion, and toxicity (ADMET). Thus, compound 40 is expected to be a promising therapeutic agent or chemical tool for the investigation of life process.

SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS

The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors. Formula(I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.